Show simple item record

dc.contributor.authorThorneloe, Rachael Janeen
dc.contributor.authorHall, Louise Hazelen
dc.contributor.authorWalter, Fionaen
dc.contributor.authorSide, Lucyen
dc.contributor.authorLloyd, Kelly Elizabethen
dc.contributor.authorSmith, Samuel Georgeen
dc.date.accessioned2020-01-10T00:31:04Z
dc.date.available2020-01-10T00:31:04Z
dc.date.issued2020-01-27en
dc.identifier.issn1940-6207
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/300700
dc.description.abstractTamoxifen reduces breast cancer incidence in women at increased risk, but may cause side-effects. We examined women’s knowledge of tamoxifen’s potential harms and benefits, and the extent to which knowledge reflects subjective judgements of awareness and decision quality. After a hospital appointment, 408 (55.7%) women at increased risk of breast cancer completed a survey assessing objective knowledge about the potential benefit (risk reduction) and harms (endometrial cancer, thromboembolic events, and menopausal side-effects) of tamoxifen, and subjective tamoxifen knowledge and decisional quality. 258 (63.2%) completed a 3-month follow-up survey. 15.7% of participants recognised the potential benefit and three major harms of using tamoxifen. These women were more likely to have degree level education (vs. below degree level) (OR=2.24, 95%CI: 1.11-4.55) and good numeracy (vs. poor numeracy) (OR=5.91, 95%CI: 1.33-26.19). Tamoxifen uptake was higher in women who recognised all harms and benefits (vs. not recognising) (OR=2.47, 95%CI: 0.94–6.54). 65.8% of tamoxifen users were unaware of its potential benefit and harms. Most (87.1%) women reported feeling informed about tamoxifen, and subjective decisional quality was high (Mean [SD], 17.03 [1.87], out of 18). Knowledge regarding the potential harms and benefit of tamoxifen is low in women considering prevention therapy, and they may need additional support to make informed decisions about tamoxifen preventive therapy.
dc.format.mediumPrint-Electronicen
dc.languageengen
dc.publisherAmerican Association for Cancer Research
dc.rightsAll rights reserved
dc.rights.uri
dc.titleKnowledge of potential harms and benefits of tamoxifen among women considering breast cancer preventive therapy.en
dc.typeArticle
prism.publicationDate2020en
prism.publicationNameCancer prevention research (Philadelphia, Pa.)en
dc.identifier.doi10.17863/CAM.47773
dcterms.dateAccepted2020-01-21en
rioxxterms.versionofrecord10.1158/1940-6207.capr-19-0424en
rioxxterms.versionAM
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.licenseref.startdate2020-01-27en
dc.contributor.orcidHall, Louise Hazel [0000-0001-9032-4540]
dc.contributor.orcidWalter, Fiona [0000-0002-7191-6476]
dc.identifier.eissn1940-6215
rioxxterms.typeJournal Article/Reviewen
cam.orpheus.successTue Mar 31 10:37:46 BST 2020 - Embargo updated*
cam.orpheus.counter2*
rioxxterms.freetoread.startdate2021-01-27


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record